Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV

Phillip Chan,1 Payal Patel,2 Joanna Hellmuth,3 Donn J. Colby,1 Eugene Kroon,1 Carlo Sacdalan,1 Suteearporn Pinyakorn,4 Linda Jagodzinski,4 Shelly Krebs,4,5 Jintanat Ananworanich,1,4,5 Victor Valcour,3 Serena Spudich2,6; on behalf of the RV254/SEARCH 010 Study Team

1SEARCH Thailand, Thai Red Cross AIDS Research Centre, Bangkok; 2Department of Neurology, Yale University School of Medicine, New Haven, Connecticut; 3Memory and Aging Center, Department of Neurology, University of California San Francisco; 4U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland; 5Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland; 6Center for Neuroepidemiology and Clinical Neurological Research, Yale University, New Haven, Connecticut

Our understanding of central nervous system (CNS) involvement in human immunodeficiency virus (HIV) infection has evolved over the last 2 decades. The transmigration of HIV into the CNS from the systemic circulation is thought to initiate neuropathogenic processes, including forms of HIV encephalitis (HIVE) and HIV-associated neurocognitive disorder. These processes can occur across all stages of HIV infection and treatment and are not solely determined by markers of HIV disease severity such as current CD4+ T-lymphocyte count [1, 2]. In particular, it has become clear that the CNS is affected early in the course of infection, evidenced by the detection of HIV ribonucleic acid (RNA) in the cerebrospinal fluid (CSF) as early as 8 days from transmission [3], frequent neurological signs and symptoms during acute HIV infection [4], and abnormalities in neuroimaging and CSF markers of inflammation during acute and primary HIV infection [5, 6].

The entrance of HIV into the CNS ultimately leads to infection of resident CNS cells including microglia and astrocytes, setting the stage for the potential of HIV persistence even after antiretroviral therapy is initiated. The potential of the CNS as reservoir for HIV is supported by symptomatic CSF viral escape [7, 8]—a measurable CSF HIV RNA level with an undetectable plasma level in treated individuals presenting with neurological disease—and the isolation of CNS-specific viral strains through sequencing and phylogenetic studies [9–11]. Understanding the viral dynamics between the systemic circulation and the CNS compartment is crucial to elucidate the pathogenesis of HIV-related neurological injury and the development of CNS reservoirs. However, the literature to date is primarily based on samples of treatment-naïve, chronically HIV-infected individuals, in whom CSF HIV RNA level is closely associated with that in plasma and the severity of immunodeficiency [12–15]. Reports from primary infection cohorts (within months of initial infection) suggest a similar...
relationship between CSF and plasma HIV RNA levels but with a larger difference between the 2 compartments [5, 16]. The relationship between plasma and CSF HIV RNA levels during the earliest weeks of HIV infection is unknown. Understanding these factors may allow development of strategies to effectively prevent establishment of reservoirs in the CNS and HIV related injury. We examined paired blood and CSF HIV RNA data from the SEARCH010/RV254 cohort, a prospective longitudinal study in Bangkok, Thailand, aiming to define the viral dynamics between CSF and plasma across various Fiebig stages and to identify factors associated with CSF HIV RNA level.

METHODS

Study Design and Participants
We selected participants enrolled into the SEARCH010/RV254 cohort between April 2009 and December 2016 with available CSF data. Methodology and primary goals of this cohort study have been described elsewhere [3, 4]. In brief, these individuals were enrolled through voluntary HIV counseling and testing services offered in Bangkok and Pattaya, Thailand, where specimens were systematically screened for acute HIV infection. Enrolled participants were classified into Fiebig stages I to V defined by a hierarchical algorithm from pooled nucleic acid testing, sequential immunoassay, p24 antigen, and Western blot testing [17]: Fiebig I: RNA+, p24 antigen−; Fiebig II: p24 antigen+, IgM−; Fiebig III: IgM+, Western blot−; Fiebig IV: Western blot indeterminate; Fiebig V: Western blot+ without p31 protein band [17]. All participants were assessed at acute infection, immediately initiated combination antiretroviral therapy (cART), and were then followed longitudinally for up to 10 years. The current analysis focused on baseline, cross-sectional pre-cART data. Optional lumbar punctures (LP) were typically performed within 48 hours of acute HIV infection confirmation. All participants provided written informed consent to participate in the study. The study protocol was approved by the institutional review boards of Chulalongkorn University (Bangkok, Thailand), Walter Reed Army Institute of Research (Silver Spring, MD), University of California, San Francisco (San Francisco, CA), and Yale University (New Haven, CT).

Clinical Data and Laboratory Measures
Demographic and clinical parameters of LP participants were collected at baseline, including CD4+ and CD8+ T-lymphocyte count, plasma HIV RNA level, Fiebig stage (I to V), and the presence of acute retroviral syndrome, defined as ≥3 qualifying symptoms using a standardized checklist. Cerebrospinal fluid and plasma HIV viral RNA quantification were completed using the Roche Amplicor HIV-1 Monitor Test V1.5 or Roche COBAS TaqMan HIV-1 V2.0. The lower limit of quantification of plasma HIV RNA was 50 and 20 copies/mL, respectively, depending on the platform used. The lower limit of quantification of CSF HIV RNA was 80 copies/mL. In the following data analyses, a level of 80 copies/mL was assigned to the CSF samples with HIV RNA below the lower limit of quantification.

Cerebrospinal Fluid Soluble Marker Analysis
Cerebrospinal fluid inflammatory markers reflecting T-lymphocyte recruitment (CXCL10) and monocyte/macrophage (interleukin [IL]-6, CCL2, soluble [s]CD163, sCD14, and neopterin) recruitment and activation were evaluated in parallel to HIV RNA level in a subgroup of LP participants. Cerebrospinal fluid IL-6, sCD163, CXCL10, and CCL2 were quantified using a Luminex multiplex enzyme-linked immunosorbent assay (ELISA) array (EMD Millipore, Billerica, MA) per manufacturer’s instructions. Data were collected on a FlexMap 3D system. A subset of samples assessed early during the course of the trial were quantified for CXCL10 and CCL2 by custom ELISA array (Quansys Biosciences, Logan, UT). Data generated from this platform were normalized to the Luminex platform by testing of replicate samples assessed in paired assays. Neopterin (GenWay Biotech, San Diego, CA) and sCD14 (R&D Systems, Minneapolis, MN) were measured by standard chemiluminescent detection ELISA per manufacturer’s instructions and read on a VersaMax reader (Molecular Devices, Sunnyvale, CA). All data were analyzed in Prism version 6.0 for Mac OS X (GraphPad, La Jolla, CA) using a 4-parameter fit standard curve.

Statistical Analysis
Human immunodeficiency virus-1 RNA levels were transformed to log_{10} for analysis. The viral dynamic between plasma and CSF compartments was represented by the plasma to CSF viral load ratio (PC_{ratio}), calculated as log_{10} (plasma HIV RNA level/CSF HIV RNA level), and mathematically equivalent to log_{10} plasma HIV RNA minus log_{10} CSF HIV RNA. A PC_{ratio} less than 1 indicates the CSF HIV RNA level is greater than one tenth of that in the plasma, a frequently cited reference in untreated chronic infection. Results were reported as median and interquartile range (IQR) or frequency and percentage, as appropriate. Fisher’s exact test and the non-parametric Mann-Whitney U test were used to compare categorical and continuous variables, respectively. Factors associated with CSF HIV RNA level and PC_{ratio} were examined using a linear regression model. Factors with a P value <.10 in univariate analysis were included in the subsequent multivariable analysis using the backward stepwise method. Statistical analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY).

RESULTS

Characteristics of Study Participants
During the sampling period, 430 individuals were enrolled into SEARCH010/RV254. Among these, 117 (27%) underwent baseline LP. The LP participants had similar demographic (age, sex) and HIV infection parameters (plasma HIV RNA level, Fiebig stages, and percentage of acute retroviral syndrome
Acid Levels in Acute HIV Infection

Cerebrospinal Fluid Human Immunodeficiency Virus (HIV) Ribonucleic Acid Levels in Acute HIV Infection

Among the 117 CSF samples, 90 (77%) had quantifiable HIV RNA, 18 (15%) had undetectable HIV RNA, and 9 (8%) had detectable HIV RNA but an unquantifiable level. Cerebrospinal fluid and plasma viral loads with respect to days after estimated HIV exposure were shown in Figure 1. Overall, the CSF HIV RNA measurable rate was 51% (22 of 43) among early enrollees (Fiebig I and II) and 92% (68 of 74) for participants enrolling during later Fiebig stages (Fiebig III to V). Table 1 shows the demographic and laboratory data of participants grouped according to the CSF HIV RNA quantification status. The group with quantifiable CSF HIV RNA levels presented more often at Fiebig III or later (P < .001) and had lower CD4+ lymphocyte count (P = .002), higher CD8+ lymphocyte count (P = .009), higher plasma HIV RNA level (P < .001), and more frequent acute retroviral syndrome presentation (P = .001). Among those with quantifiable CSF HIV RNA levels, the median PC\textsubscript{ratio} was 2.36 log\textsubscript{10} copies/mL and ranged from 0.10 to 4.40 log\textsubscript{10} copies/mL.

Figure 1. Cerebrospinal fluid (CSF) and plasma human immunodeficiency virus (HIV) ribonucleic acid (RNA) levels with respect to days after estimated HIV exposure. A level of 80 copies/mL was assigned to those who had a CSF HIV RNA level below quantification.

Variability of Plasma-Cerebrospinal Fluid Human Immunodeficiency Virus Ribonucleic Acid Level Difference and Its Determinant

The CSF vs plasma HIV RNA level distribution color-coded by Fiebig stage is shown in Figure 3. Dotted lines of 1–3 log PC\textsubscript{ratio} were added for reference. Cerebrospinal fluid HIV RNA level, as shown in the regression model, positively correlates with the plasma HIV RNA level. Among the 27 individuals who had a CSF HIV RNA level below the level of detection, half (n = 14) presented at Fiebig stage I, 7 at Fiebig stage II, and the remainder from Fiebig stage III to V. Moreover, one quarter (n = 7) had a relatively high plasma HIV RNA level above 5 log\textsubscript{10} despite the unmeasurable CSF HIV RNA level.

Another 7 individuals had a high level of HIV RNA in CSF with respect to the level in plasma, resulting in a PC\textsubscript{ratio} below 1 log. This group of outliers (PC\textsubscript{ratio} <1) was not dominated by late enrollees (3 at Fiebig II; 2 at Fiebig III; 1 at Fiebig IV; and 1 at Fiebig V), and they were infected by a similar HIV subtype as others (6 by CRF01_AE and 1 by recombinant subtype CRF01_AE/B). There were no differences between the outliers, and the rest of group with quantifiable CSF HIV RNA in plasma HIV RNA level (P = .224), rate of acute retroviral syndrome presentation (P = .889), and duration of infection according to Fiebig staging (P = .377).

Linear regression modeling was performed to evaluate the potential factors associated with PC\textsubscript{ratio} across the entire group (Table 3). In univariate analyses, only CD8 lymphocyte count...
and CD4/CD8 ratio achieved a $P$ value <.05. In the multivariable analysis, CD4/CD8 ratio was the only significant factor, showing a positive correlation ($P = .018$, adjusted $\beta$ coefficient = 0.380).

**Comparison of Cerebrospinal Fluid Immune Activation Markers According to Cerebrospinal Fluid Human Immunodeficiency Virus Detection and PCratio Status**

We compared the levels of the 6 CSF biomarkers of immune activation (neopterin, sCD14, IL-6, CXCL10, CCL2, sCD163) in a subgroup of LP participants categorized by CSF HIV RNA and PCratio: CSF HIV RNA <80 copies/mL (lower limit of quantification) vs CSF HIV RNA level $\geq$80 copies/mL with PCratio >1 vs CSF HIV RNA level >80 copies/mL with PCratio $\leq$1 (outliers) (Figure 4). In general, all CSF immune activation markers increased with quantifiable CSF HIV RNA, and they were highest in the outlier group. In particular, the group of participants with CSF HIV RNA below quantification had statistically lower levels of all CSF cytokines except sCD14 (all $P < .05$). The outlier group, despite having similar Fiebig staging composition and plasma HIV RNA level to the group with PCratio >1, showed a significantly higher CSF neopterin, sCD163, IL-6, and sCD14 (all $P < .05$).

**DISCUSSION**

We have previously reported a high rate of CSF HIV RNA detection (15 of 18) in study participants with acute HIV infection, with detectable CSF HIV RNA as early as 8 days after estimated infection [3]. In the current analysis, the rate of HIV RNA above the lower limit of quantification in CSF was 51% at Fiebig I and

---

Table 1. Demographic and Clinical Parameters According to CSF HIV RNA Detection Status

| Characteristics | <LOQ (n = 27) | $\geq$LOQ (n = 90) | P Value |
|-----------------|---------------|-------------------|--------|
| Male, n (%)     | 26 (96)       | 87 (97)           | 1.00   |
| Age (year)      | 26.0 (23–31)  | 27.5 (23–32)      | .902   |
| CD4 T lymphocytes (cells/µL) | 555 (354–699) | 384 (280–506) | .002   |
| CD8 T lymphocytes (cells/µL) | 442 (238–586) | 624 (368–1013) | .009   |
| CD4/CD8 ratio   | 1.12 (0.59–1.57) | 0.68 (0.38–0.95) | <.001  |

Fiebig Stage

| and II, n (%) | 21 (78) | 22 (24) |
| III to V, n (%) | 6 (22) | 68 (76) | <.001 |

Plasma HIV RNA (log$_{10}$ copies/mL) 4.23 (0.92) 6.14 (5.48–6.83) <.001

CSF HIV RNA (log$_{10}$ copies/mL) 1.90 (0.0) 3.76 (2.81–4.82) <.001

Plasma-CSF HIV RNA Ratio (PCratio) (range, log$_{10}$ copies/mL)$^c$ - 2.36 (0.10–4.40) <.001

Presence of ARS, n (%) 14 (52) 77 (86) .001

Active syphilis, n (%)$^d$ 2 (7) 6 (7) 1.00

Abbreviations: ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; LOQ, lower limit of quantification (80 copies/mL); RNA, ribonucleic acid; RPR, Rapid Plasma Reagin; VDRL, Venereal Disease Research Laboratory.

$^a$Results shown are presented as median (interquartile range) unless specified.

$^b$A level of 80 copies/mL was assigned to those who had a CSF HIV RNA level below quantification.

$^c$Plasma-CSF HIV RNA Ratio (PCratio) = log$_{10}$ plasma HIV RNA minus log$_{10}$ CSF HIV RNA.

$^d$Defined as positive Treponema pallidum hemagglutination and RPR/VDRL, with no treatment 3 months before the acute HIV infection diagnosis.

---

Figure 2. Human immunodeficiency virus (HIV) ribonucleic acid (RNA) level by Fiebig stage (a) plasma and (b) cerebrospinal fluid (CSF). Median (solid line), interquartile range (extent of boxes), 1.5 times of interquartile range (whiskers), and outliers/extreme outliers (stars) are indicated. Number of participants by Fiebig stage (n): I (19); II (24); III (52); IV (15); V (7). A level of 80 copies/mL was assigned to those who had a CSF HIV RNA level below quantification.
II and 92% at Fiebig III to V. Our findings provide additional evidence that HIV can invade the CNS at the earliest phase of infection. In addition, our assessment of immune activation biomarkers indicates that HIV invasion is not a silent event and is associated with an extensive CNS immunologic response.

Table 2. Linear Regression Analysis on CSF HIV RNA Level (n = 117)*

| Characteristics        | Univariate Analysis | Multivariable Analysis |
|------------------------|--------------------|------------------------|
|                        | β Coefficient (95% CI) | PValue | Adjusted β Coefficient (95% CI) | PValue |
| Age (years)            | −0.001 (−0.031 to 0.028) | .93    | −0.604 (0.470 to 0.738) | <.001 |
| Sex                    |                   |         | NS                           |         |
| Male                   |                   |         | Ref                          |         |
| Female                 | 0.922 (−0.266 to 2.111) | .127   | 0.604 (0.470 to 0.738) | <.001 |
| Plasma HIV RNA (log10 copies/mL) | 0.688 (0.547 to 0.823) | <.001 | 0.604 (0.470 to 0.738) | <.001 |
| CD4 (per 100 cells/µL) | −0.273 (−0.385 to −0.161) | <.001 | NS                           |         |
| CD8 (per 100 cells/µL) | 0.040 (0.006 to 0.074) | .022   | NS                           |         |
| CD4/CD8                | −0.977 (−1.334 to −0.620) | <.001 | −0.616 (−0.903 to −0.330) | <.001 |
| Fiebig Stage           |                   |         | NS                           |         |
| III and later          |                   |         | Ref                          |         |
| I and II               | −1.238 (−1.629 to −0.848) | <.001 | NS                           |         |
| Active Syphilis*       |                   |         | NS                           |         |
| No                     |                   |         | Ref                          |         |
| Yes                    | 1.047 (0.559 to 1.535) | <.001 | NS                           |         |

Abbreviations: ARS, acute retroviral syndrome; CI, confidence interval; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; NS, not significant; Ref, reference; RNA, ribonucleic acid; RPR, Rapid Plasma Reagin; VDRL, Venereal Disease Research Laboratory.

* A level of 80 copies/mL was assigned to those who had a CSF HIV RNA level below quantification. Factors with P < .1 in the univariate analysis were included into the multivariate analysis.

**Defined as positive Treponema pallidum hemagglutination and RPR/VDRL, with no treatment 3 months before the acute HIV infection diagnosis.

Our cohort provides a novel parallel comparison between plasma and CSF CSF HIV RNA level across Fiebig stages in acute HIV infection, in which the CSF HIV RNA level peaked at Fiebig IV whereas the plasma HIV RNA peaked at Fiebig III. This is in line with recent studies that report a systemic HIV-specific T-cell expansion and cytokine burst taking place during Fiebig III in both human and primate models [18–20]. Moreover, in a prior report from this cohort, the frequency of activated CD8 T lymphocytes was elevated in CSF samples from later Fiebig stages compared with those from earlier stages [21]. Because the brain is an immune privileged site bound by the blood-brain barrier (BBB), it may delay the entry of infected cells into the CNS, and hence there is a delayed HIV viral expansion in CSF in comparison with plasma [22, 23].

Determinants of Cerebrospinal Fluid Human Immunodeficiency Virus Ribonucleic Acid Level

To date, most CSF HIV RNA level studies have come from chronic HIV infection cohorts and occasionally primary HIV infection cohorts defined as within 1 year of HIV transmission. Plasma HIV RNA has been reported to be predictive of that in CSF [5, 12, 13]. Severity of immunosuppression [24], concomitant CNS opportunistic infection [12, 15], and presence of HIVIE [14, 15] may also be independently associated with the CSF HIV RNA level. Our analysis is unique in that we assessed viral dynamics from the bloodstream and CSF at the stage of CNS invasion. By contrast, chronic HIV infection represents a stage of equilibrium in which local viral replication in CNS has already been established and multiple confounding factors may impact CSF HIV RNA level.
Although the exact mechanism of HIV CNS entry has not been elucidated, pathways such as free virus entry or a cell-mediated cascade have been hypothesized [25]. The cell-mediated, or so-called “Trojan horse” mechanism, is the most accepted theory, in which HIV is transported across the BBB by infected CD4+ lymphocytes and monocytes. After seeding of

**Table 3. Linear Regression Analysis on Plasma CSF HIV RNA Ratio (PCratio) (N = 117)\(^a\)**

| Characteristics | Univariate analysis | Multivariable analysis |
|-----------------|---------------------|-----------------------|
|                 | \(\beta\) Coefficient (95% CI) | \(P\) Value | Adjusted \(\beta\) Coefficient (95% CI) | \(P\) Value |
| Age             | 0.012 (−0.012 to 0.035) | .320 | 0.380 (0.068 to 0.692) | .018 |
| Sex             | Male Ref | | | |
| CD4 (per 100 cells/µL) | −0.064 (−0.162 to 0.034) | .198 | 0.380 (0.068 to 0.692) | .018 |
| CD8 (per 100 cells/µL) | −0.029 (−0.056 to −0.001) | .040 | | NS |
| CD4/CD8         | 0.380 (0.068 to 0.692) | .018 | 0.380 (0.068 to 0.692) | .018 |

**Figure 4.** Levels of cerebrospinal fluid (CSF) immune and inflammatory markers in participants grouped by CSF human immunodeficiency virus (HIV) ribonucleic acid (RNA) quantification and PCratio status: CSF HIV RNA below the lower limit of quantification (<LOQ), quantifiable CSF HIV RNA with PCratio >1 (PCratio >1), and quantifiable CSF HIV RNA with PCratio <1 (PCratio <1). Median (middle line), interquartile range (extent of boxes), 1.5 times of interquartile range (whiskers), and outliers/extreme outliers (colored dots) are indicated. \(P\) value of non-parametric test between groups are shown. Dotted horizontal line: median level of 22 unmatched HIV-negative Thai controls. All markers level are presented in pg/mL. PCratio = \(\log_{10}\) plasma HIV RNA minus \(\log_{10}\) CSF HIV RNA. Abbreviation: PCratio, plasma-CSF HIV RNA ratio.

Abbreviations: ARS, acute retroviral syndrome; CI, confidence interval; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; NS, not significant; Ref, reference; RNA, ribonucleic acid; RPR, Rapid Plasma Reagin; VDRL, Venereal Disease Research Laboratory.

\(^a\)A level of 80 copies/mL was assigned to those who had a CSF HIV RNA level below quantification. Factors with \(P < .1\) in the univariate analysis were included into the multivariate analysis.

\(^b\)Defined as positive Treponema pallidum hemagglutination and RPR/VDRL, with no treatment 3 months before the acute HIV infection diagnosis.
the intracerebral perivascular space, local CNS cells including microglia, tissue macrophages, and possibly astrocytes are infected [26, 27]. The positive correlation between plasma and CSF HIV RNA level in the linear regression model would support either free virus or a cell-mediated cascade hypotheses.

**Predictors of Viral Penetration Into Central Nervous System**

Previous CSF versus plasma analyses from primary HIV infection cohorts revealed a larger PC ratio than seen in chronic infection [5, 16]. In addition to this observation, we noted a surprisingly large variation of PC ratio in our group of participants. Although some had a high PC ratio with CSF HIV RNA level below the level of detection in conjunction with high plasma HIV RNA, there was also a group of outliers who had an exceptionally low PC ratio that was similar to that seen in chronic infection [24, 28]. These outliers exhibited heightened CNS immune activation as demonstrated by significantly higher levels of CSF cytokines including neopterin, CXCL10, sCD14, and sCD163.

Our study demonstrates that initial viral invasion into the CNS was only partially governed by the duration of HIV infection, with the lowest rate of measurable CSF HIV RNA of 26% at Fiebig stage I, progressively increasing to over 90% in Fiebig III to V. It is interesting to note that the PC ratio did not correlate with Fiebig stage. Taking Fiebig stage II CSF samples as example, although the rate of measurable CSF HIV RNA level in this group was lower than that of Fiebig stage III to V, 3 of 7 PC ratio outliers came from Fiebig II. This paradoxical finding may suggest that HIV dynamics between the systemic circulation and the CNS, once established, are no longer altered by duration of infection.

The correlation of CD4/CD8 ratio with both CSF HIV RNA level and PC ratio further suggests an independent role of the immune response in modulating viral trafficking across the BBB. Indeed, there is a growing body of literature regarding the relevance of CD4/CD8 ratio as a marker of the immunologic state in both HIV-infected and uninfected populations. In uninfected individuals, a low CD4/CD8 ratio is associated with the immunosenescent state in which T-cell effector reaction and vaccination immunogenicity are hypofunctional [29, 30]. In treated HIV-infected individuals, a persistently low CD4/CD8 ratio represents immunologic dysfunction that is associated with ongoing heightened immune activation [31, 32]. Clinically, a low CD4/CD8 ratio has been linked with impaired cognitive performance [33], vascular complications, malignancy, and mortality in HIV populations [34]. Moreover, a previous cellular composition study found a linked distortion of CD4/CD8 ratio between plasma and CSF samples from HIV-infected individuals [35]. These findings suggested that the CD4/CD8 ratio may serve as an immunologic state marker independent of absolute CD4 or CD8 T-lymphocyte counts.

In light of the recent findings in treatment-naïve and treated HIV-infected populations correlating cognitive impairment and high CSF/plasma HIV RNA ratio [28] and low CD4/CD8 ratio [33], respectively, we hypothesize that a lower CD4/CD8 ratio would give rise to early seeding of the CNS reservoir and hence a higher CSF/plasma HIV RNA ratio through enhanced viral penetration. In treated HIV infection, given BBB permeability defects not readily reverted by cART [36] and the association of low CD4/CD8 ratio with increased HIV systemic reservoir size [37, 38] and more frequent viral blips [39], HIV may continue to breach the BBB directly through low-level viremia or indirectly carried by activated immune cells. Both scenarios, pre- and posttreatment, could seed the CNS with a larger pool of infected and immune-activated cells and set the stage for inflammatory-driven injury. In a recent study of HIV-infected participants on suppressive ART using a neurocognitive assessments and a positron emission tomography (PET) radioligand ([11C]PBR28) to measure brain microglial activation, a low CD4/CD8 ratio was associated with heightened CNS immune activation by PET, which, in return, was associated with altered white matter structure in magnetic resonance imaging and poorer cognitive performance [40].

We observed that CD4/CD8 ratio and plasma HIV RNA level are closely associated and surmise that both may link to total body viral load during untreated acute HIV infection. However, (1) the wide spectrum of viral dynamics between plasma and CSF after Fiebig stage I and (2) the positive correlation between PC ratio and CD4/CD8 ratio suggest a modification of viral CNS penetration by the individual's immune response in addition to virologic factors. Without treatment, it is reasonable to anticipate a consequential hastening of CNS infection and injury through the increased viral penetration, which eventually leads to earlier development of neurological complications. Studies focused on treatment-naïve early HIV infection would be useful to clarify the linkage among CD4/CD8, PC ratio, and the development of cognitive impairment.

**Limitations**

This study included a population of predominantly young Thai men who sleep with men with HIV clade CRF AE_01 infection, and the findings may not be applicable to other populations. We may also overestimate the actual CSF HIV RNA level by assigning a lower limit value to those CSF HIV RNA level below the lower limit of quantification, which may affect the intergroup CSF cytokine comparisons. We also acknowledge that although CSF is one measure of CNS exposure to HIV, CSF HIV RNA level does not provide an exact index of degree of brain parenchymal infection. Finally, characterizing the viral dynamic between plasma and CSF compartments by PC ratio is an approach that fulfills linear regression model criteria but may oversimplify nonlinear relationships between the 2 compartments.

**CONCLUSIONS**

We found that the CSF HIV RNA level correlates with that in plasma at acute HIV infection. However, PC ratio is higher in acute than in chronic HIV infection, and it is highly variable. The CSF HIV RNA level peaked at Fiebig stage IV, slightly later
than the height of activation of HIV-specific blood cytotoxic T cells during Fiebig stage III. We also found that the degree of viral penetration into the CSF compared with blood could be predicted by CD4/CD8 ratio. Given a similar correlation to cognitive impairment in chronic infection, both PC_ratio and CD4/CD8 ratio may be important markers for clinically significant neurologic outcomes in both acute and chronic infection.

Notes

**Author contributions.** All authors have contributed to and approved the manuscript.

**Acknowledgments.** We thank the RV 254/SEARCH 010 participants and the International NeuroHIV Cure Consortium (INHCC.net) for support.

**Disclaimer.** The views expressed are those of the authors and do not necessarily represent the views of the US Army, the Department of Defense, or the US National Institutes of Health.

**Financial support.** This work was supported by NIH awards R01MH095613 and R01NS084911, and a cooperative agreement (W81XWH-11-2-0174) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and the US Department of Defense, with added support from the National Institutes of Mental Health.

**Potential conflicts of interest.** J. A. reports other from Viiv Healthcare, other from Merck, other from Roche, and personal fees from Gilead, outside the submitted work. V. V. reports the following: personal fees from Viiv Healthcare and personal fees from Merck, during the conduct of the study; and personal fees from IAS-USA and grants from the National Institutes of Health (NIH), outside the submitted work. S. S. reports grants from NIH, National Institute of Mental Health and National Institute of Neurological Disorders and Stroke, during the conduct of the study, and nonfinancial support from Viiv Healthcare, Inc., outside the submitted work. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Wright EJ, Grund B, Cysique LA, et al. Factors associated with neurocognitive performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16:97–108.
2. Brew BJ, Perdices M, Darveniza P, et al. The neurological features of early and ‘latent’ human immunodeficiency virus infection. Aust N Z J Med 1989; 19:700–5.
3. Valcour V, Chalermchai T, Sailsasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012; 206:275–82.
4. Hellmuth J, Fletcher JL, Valcour V, et al. Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology 2016; 87:148–54.
5. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011; 204:753–60.
6. Ragin AB, Wu Y, Gao Y, et al. Brain alterations within the first 100 days of HIV infection. Ann Clin Transl Neurol 2015; 2:12–21.
7. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773–8.
8. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012; 26:1765–74.
9. Tong CY, Costelloe S, Hubb J, et al. Deep sequencing of HIV-1 in cerebrospinal fluid. Clin Infect Dis 2015; 61:1022–5.
10. Béguelin C, Vázquez M, Bertschi M, et al. Viral escape in the CNS with multidrug-resistant HIV-1. J Int AIDS Soc 2014; 17:19745.
11. Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog 2015; 11:e1004720.
12. Chang CC, Kangetha R, Omarjee S, et al. Relationship of human immunodeficiency virus viral load in cerebrospinal fluid and plasma in patients co-infected with cryptococcal meningitis. Open Forum Infect Dis 2017; 4:ofx032.
13. Christo PP, Greco DB, Aleixo AW, Livramento JA. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis 2007; 7:147.
14. Cinque P, Vago L, Ceresa D, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998; 12:389–94.
15. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997; 175:963–6.
16. Tambussi G, Gori A, Capiluppi B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 2000; 30:962–5.
17. De Souza MS, Phanupak N, Pinyakorn S, et al. Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS 2015; 29:793–800.
18. Takata H, Buranapraditkun S, Kessing C, et al. Delayed differentiation of potent effector CD8+ T cells reducing
viremia and reservoir seeding in acute HIV infection. Sci Transl Med 2017; 9:eaaq1809.

19. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719–33.

20. Li Q, Skinner PJ, Ha SJ, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726–9.

21. Kessing CF, Spudich S, Valcour V, et al. High number of activated CD8+ T cells targeting HIV antigens are present in cerebrospinal fluid in acute HIV infection. J Acquir Immune Defic Syndr 2017; 75:108–17.

22. Dahm T, Rudolph H, Schwerk C, Schroten H, Tenenbaum T. Neuroinvasion and inflammation in viral central nervous system infections. Mediators Inflamm 2016; 2016:8562805.

23. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33:579–89.

24. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.

25. McGavern DB, Kang SS. Illuminating viral infections in the nervous system. Nat Rev Immunol 2011; 11:318–29.

26. Li GH, Henderson L, Nath A. Astrocytes as an HIV reservoir: mechanism of HIV infection. Curr HIV Res 2016; 14:373–81.

27. Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS 2013; 8:165–9.

28. Bai F, Iannuzzi F, Merlini E, et al. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naive HIV-infected patients. AIDS 2017; 31:311–4.

29. Wherry EJ. T cell exhaustion. Nat Rev Immunol 2011; 12:492–9.

30. Tsoukas C. Immunosenescence and aging in HIV. Curr Opin HIV AIDS 2014; 9:398–404.

31. Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a front tier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015; 18:20052.

32. Serrano-Villar S, Gutiérrez C, Vallejo A, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 2013; 66:57–66.

33. Vassallo M, Fabre R, Durant J, et al. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. J Neurovirol 2017; 23:216–25.

34. Castilho JL, Shepherd BE, Koethe J, et al. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS 2016; 30:899–908.

35. Ho EL, Ronquillo R, Altmeppen H, Spudich SS, Price RW, Sinclair E. Cellular composition of cerebrospinal fluid in HIV-1 infected and uninfected subjects. PLoS One 2013; 8:e66188.

36. Rahimy E, Li FY, Hagberg L, et al. Blood-brain barrier disruption is initiated during primary HIV infection and not rapidly altered by antiretroviral therapy. J Infect Dis 2017; 215:1132–40.

37. Cockerham LR, Siliciano JD, Sinclair E, et al. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS One 2014; 9:e110731.

38. Chun TW, Justement JS, Pandya P, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185:1672–6.

39. Zoufaly A, Kiepe JG, Hertling S, et al. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. HIV Med 2014; 15:449–57.

40. Vera JH, Guo Q, Cole JH, et al. Neuroinflammation in treated HIV-positive individuals: a TSPO PET study. Neurology 2016; 86:1425–32.